Forgot your password?

Forgot your username?

BioNeutral to Expand Into Asia

Written by on May 16, 2009




Print Friendly Print Get a PDF version of this webpage PDF

BioNeutral Group, a developer of chemical-based technology, announced that they will form a new wholly owned subsidiary in Hong Kong to commercialize their proprietary chemical formulations throughout Asia. The Newark, NJ, company has been flooded with inquiries from China and India regarding the effectiveness of their Ygiene antimicrobial formulation against the deadly swine flu virus. BioNeutral markets Ygeine through its wholly owned subsidiary, Advanced Bio-Fiber Treatments Corp.

Ygeine and Ogeine are “green” formulas that utilize combinational chemistry-based technology to neutralize environmental contaminants, toxins, and dangerous microorganisms such as spores and viruses. The market for antimicrobial treatments that can be applied to clothing and textiles is expanding, particularly in areas that have a high risk of exposure to chemicals and pathogens. BioNeutral has offered Ygiene to the U.S. Centers for Disease Control for testing to determine the product’s effectiveness against the swine flu virus.

The global incidence of swine flu is approaching pandemic levels. Over 8,400 people worldwide have contracted the H1N1 virus to date, with 72 deaths. In late April, the World Health Organization raised the pandemic alert to 5 on a 6-point scale, meaning a pandemic is imminent. The disease has reached 36 countries; Turkey and India confirmed their first cases on Saturday.

Related video: Stephen Browand, President and CEO of BioNeutral Group



No Responses to “BioNeutral to Expand Into Asia”

  1. » Companies Rush to Create Swine Flu Vaccines | OneMedPlace » Archive says:
    June 5, 2009 at 5:03 pm

    [...] Related post: BioNeutral to Expand Into Asia [...]

  2. » BioNeutral Ships Mold-Fighting Ogiene-M Formulation | OneMedPlace » Archive says:
    June 22, 2009 at 2:46 pm

    [...] harmful environmental contaminants and toxins. Earlier this year, the New Jersey-based company announced plans to create a new wholly-owned subsidiary in Hong Kong. BioNeutral is a client of the Enterprise Development Center, a high-tech business [...]

  3. » Independent Study Validates BioNeutral’s Ygiene | OneMedPlace » Archive says:
    July 8, 2009 at 11:13 am

    [...] Dr. Andy Kielbania, BioNeutral’s Chief Science Officer, stated in a press release, “These results are particularly important because they both validate our internal lab testing protocols and also confirm the speed, efficacy and power of our Ygiene antimicrobials.” The company is confident that Ygiene can kill antibiotic-resistant bacteria such as MRSA, and aggressive viruses such as the H1NI “swine flu” virus. BioNeutral has been swamped with inquiries from China and India about Ygiene’s potential to kill H1N1. In May, the company announced plans to expand into Asia.  [...]

Leave a Reply